Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Phase I trial of HS-20110, a novel antibody drug conjugate for advanced solid tumors
This open-label, multicenter Phase I trial evaluates HS-20110’s safety, tolerability, pharmacokinetics and initial efficacy in patients with advanced solid malignant tumors. The study includes a dose escalation…
NCT06892379 First-in-human - New trial
Lymphoma
Phase 1 ZE50-0134 Investigational BCL‑2 Inhibitor in Relapsed Lymphoid Malignancies
This trial by Eilean Therapeutics evaluates ZE50-0134, a novel BCL‑2 inhibitor, for safety, pharmacokinetics, and preliminary efficacy in patients with relapsed and refractory chronic lymphocytic leukemia, small…
NCT06708897 First-in-human - New trial
Lymphoma
Phase 1 study of CBX-250, an investigational Cathepsin G Peptide-HLA-Targeting T Cell Engager
This Phase 1 open-label dose-escalation trial at Crossbow Therapeutics evaluates the safety and preliminary activity of subcutaneous CBX-250 given in 28-day cycles (with an initial priming phase) in patients aged 12…
NCT06994676 First-in-human - Trial result
Non-small cell lung cancer
Durvalumab + Oleclumab (CD73) or Monalizumab (NKG2A) Lowers PFS Hazard ≈40% in Unresectable Stage III NSCLC
Durvalumab, an anti‑PD‑L1 antibody, was paired with oleclumab (anti‑CD73) or monalizumab (anti‑NKG2A) in the open‑label phase 2 COAST trial (NCT03822351) enrolling 189 patients with unresectable stage III NSCLC and…
NCT03822351 - Trial result
Non-small cell lung cancer
Encorafenib + Binimetinib (BRAF/MEK) Delivers 75% ORR and 30 mo PFS in BRAF V600E mNSCLC
Encorafenib, a BRAF inhibitor, plus the MEK inhibitor binimetinib was tested in the single‑arm Phase 2 PHAROS study (NCT03915951), treating 59 untreated and 39 previously treated BRAF V600E‑mutant metastatic NSCLC…
NCT03915951 - Trial result Spotlight
Lymphoma
Finite‑Course Venetoclax (BCL‑2) Delivers 36 mo Median PFS in Relapsed Waldenström Macroglobulinemia
Venetoclax, an oral BCL‑2 inhibitor, was given at 200→800 mg daily for up to 2 years in a single‑arm phase 2 trial (NCT02677324) of 32 previously treated WM patients (median follow‑up 81 mo). Median progression‑free…
NCT02677324 - Trial result
Lymphoma
Ibrutinib + Rituximab (BTK / CD20) Lifts 48‑mo PFS to 72% in CXCR4‑Mutant Waldenström Macroglobulinemia
Ibrutinib, a covalent BTK inhibitor, plus rituximab (anti-CD20) was compared with ibrutinib alone in a pooled patient‑level analysis of three prospective studies (N=174 MYD88‑mutated WM; 58 I+R, 116 I). Overall VGPR…
- Trial result
Skin cancer (non-melanoma)
Avelumab + Cetuximab (PD‑L1 / EGFR) Halves Progression Risk vs Avelumab Alone in Advanced cSCC
Avelumab, an anti‑PD‑L1 IgG1, was paired with the EGFR antibody cetuximab in the Alliance A091802 randomized phase 2 trial (NCT03944941) enrolling 60 patients (57 evaluable) with unresectable or metastatic cutaneous…
NCT03944941 - Trial result Spotlight
Lymphoma
Calibrated CD19‑1XX CAR T Achieves 75% CR with Only 4% Grade ≥3 CRS in r/r LBCL
19(T2)28z‑1XX, a CD19 CAR T cell engineered for “just‑right” 1XX signaling, was evaluated in the first‑in‑human phase I dose‑escalation/expansion study NCT04464200. Twenty‑eight adults with relapsed/refractory large…
NCT04464200 - Trial result
Prostate cancer
NanoKnife IRE Yields 71% 12‑mo Negative Biopsy While Preserving Function in Intermediate‑Risk Prostate Cancer
Irreversible electroporation (IRE) with the NanoKnife system—brief, high‑voltage pulses that perforate cell membranes without thermal damage—was evaluated in the single‑arm pivotal PRESERVE trial (NCT04972097). 121…
NCT04972097 - Trial result
Colorectal cancer
Lonsurf (TAS‑102) Nudges ctDNA Clearance to 36% and Extends DFS to 9.4 mo in MRD‑Positive CRC
Lonsurf (TAS‑102; trifluridine / tipiracil, a thymidine‑based nucleoside analog plus thymidine‑phosphorylase inhibitor), previously approved for mCRC, was given for six 28‑day cycles in the single‑arm, phase II…
NCT05343013 - Trial result
Stomach and esophageal cancer
Avelumab + Trastuzumab/FOLFOX Posts 61% Early Response and 8 mo PFS in HER2‑Positive Metastatic G/GEJ Adenocarcinoma
Avelumab, an anti‑PD‑L1 IgG1, was paired with trastuzumab (HER2 antibody) plus mFOLFOX6 in the single‑arm phase II HCRN GI17‑319 study (NCT03783936). Eighteen previously untreated patients with HER2‑amplified…
NCT03783936 - Trial result Spotlight
Multiple solid tumors
BHV‑1510 Trop2‑TopoIx ADC Shrinks Tumors in 6/6 Patients; FGFR3 ADC BHV‑1530 Enters Clinic
BHV‑1510 is a Trop2‑targeted antibody—drug conjugate armed with Biohaven’s proprietary TopoIx topoisomerase I payload; in the first Phase 1 cohorts (monotherapy and in combo with the anti‑PD‑1 antibody cemiplimab)…
- New trial
Breast cancer
Phase 1b/2 Disitamab Vedotin ADC (tubulin inhibitor) in advanced breast cancer
This open-label trial by Pfizer evaluates disitamab vedotin monotherapy in adults with metastatic or locally advanced breast cancer expressing various HER2 levels and hormone receptors. Participants receive an IV…
NCT06966453 Exploratory - New trial
Breast cancer
Phase II Dato-DXd ADC Targeting TROP2 and Topoisomerase I in TNBC.
This prospective, interventional single-arm trial by UNC Lineberger Comprehensive Cancer Center evaluates ctDNA-based MRD in stage II/III triple negative breast cancer patients with residual disease post-neoadjuvant…
NCT07069595 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2/3 trial of BMS-986504, a selective MTA-cooperative PRMT5 inhibitor in metastatic NSCLC
This randomized study compares BMS-986504 combined with pembrolizumab and chemotherapy versus placebo regimens in first-line metastatic non-small cell lung cancer patients with homozygous MTAP deletion. BMS-986504…
NCT07063745 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase I CVHNLC mRNA immunotherapy plus pembrolizumab PD-1 inhibitor study in metastatic sqNSCLC
This open-label, first-in-human trial by CureVac evaluates safety and tolerability of investigational CVHNLC—an mRNA therapy intended to trigger anti-tumor immune responses—in combination with pembrolizumab and, in…
NCT07073183 First-in-human - New trial
Non-small cell lung cancer
Phase III Trial: Durvalumab with AZD6738 ATR inhibitor in NSCLC adjuvant setting
This randomized Phase III trial by the National Cancer Institute evaluates whether adding AZD6738, an ATR inhibitor that blocks DNA damage repair, to standard durvalumab improves time without recurrence in patients…
NCT06732401 Registrational - New trial
Non-small cell lung cancer
Phase 2: Raludotatug Deruxtecan, CDH6‐targeted ADC with an enzymatically cleavable linker
This randomized umbrella study by Merck Sharp & Dohme LLC assesses two investigational ADCs—raludotatug deruxtecan (CDH6-directed) and ifinatamab deruxtecan (B7-H3-targeting Topo1 toxin ADC)—versus docetaxel in…
NCT06780085 Exploratory - New trial
Prostate cancer
Phase II trial of JSB462 (AR inhibitor) with 177Lu vipivotide tetraxetan (PSMA-directed beta emitter)
This Phase II trial, sponsored by Novartis Pharmaceuticals, evaluates the efficacy and safety of JSB462 in combination with lutetium vipivotide tetraxetan versus lutetium vipivotide tetraxetan alone in adult men with…
NCT07047118 Exploratory - New trial
Stomach and esophageal cancer
Phase II Trial of Ivonescimab, a PD‑1/VEGF bispecific antibody, with FOLFOX in advanced gastroesophageal adenocarcinoma
Massachusetts General Hospital sponsors this single-arm, open-label Phase II study evaluating the combination of ivonescimab and FOLFOX chemotherapy (including 5‑fluorouracil inhibiting thymidylate synthase,…
NCT07070466 Exploratory - New trial
Stomach and esophageal cancer
Phase II Trial: AZD0901 CLDN18.2 ADC and rilvegostomig Tigit/PD-1 bispecific mAb in gastroesophageal cancer
This trial evaluates safety, tolerability, pharmacokinetics, and early anti-tumor activity of perioperative combination treatments in patients with locally advanced resectable gastric, gastroesophageal junction, or…
NCT07069712 Exploratory - New trial
Stomach and esophageal cancer
Phase 3 Trial of Trastuzumab Deruxtecan, a HER2-directed topoisomerase I inhibitor ADC
This randomized open-label trial compares a triplet regimen of trastuzumab deruxtecan (HER2-directed topoisomerase I inhibitor ADC) plus fluoropyrimidine and pembrolizumab with platinum-based chemotherapy plus…
NCT06731478 Registrational - New trial Spotlight
Multiple myeloma
Phase 1 GC012F Dual CAR T-cell Therapy Targeting CD19 and BCMA for Multiple Myeloma
This phase 1 study is investigating GC012F in early-line treatment for multiple myeloma, including newly diagnosed high-risk and relapsed/refractory cases. The trial uses a single infusion of a dual CAR T-cell…
NCT07073547 First-in-human - New trial
Multiple myeloma
Phase 1 trial: Mezigdomide (cereblon E3 ligase modulator) & Talquetamab (GPRC5D/CD3 bispecific mAb)
This study by Massachusetts General Hospital evaluates optimal dosing and scheduling of mezigdomide and talquetamab in patients with relapsed/refractory multiple myeloma after four or more therapies. Two sequential…
NCT07032714 Exploratory - New trial
Multiple myeloma
Phase II Trial of Elranatamab, a BCMA/CD3 bispecific antibody, in newly diagnosed multiple myeloma.
This open-label, multi-site study by SCRI Development Innovations, LLC compares consolidation and maintenance strategies after induction therapy in newly diagnosed multiple myeloma patients. In Arm A, patients…
NCT06974786 Exploratory - New trial Spotlight
Kidney cancer
Phase 1 study of 111In-XYIMSR-01 radiotracer for clear cell renal cell carcinoma detection.
An early-phase open-label study at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins evaluates the safety and tumor-targeting performance of 111In-XYIMSR-01 via SPECT/CT in participants with metastatic clear…
NCT07062549 First-in-human - New trial
Kidney cancer
Phase II trial: CBM588 (microbiome modulator) with pembrolizumab (PD-1 inhibitor)
This Phase II study at City of Hope Medical Center evaluates the addition of probiotic CBM588 to pembrolizumab versus pembrolizumab alone as adjuvant therapy in resected high-risk renal cell carcinoma. Patients…
NCT07037004 Exploratory - New trial Spotlight
Sarcoma and GIST
Phase 1 MBRT: tungsten‐slit collimator enables spatially fractionated minibeam radiation therapy
Investigating the safety and optimal dose of MBRT at Mayo Clinic, this study tests minibeam radiation—delivered via a tungsten slit collimator that creates alternating peak and valley dose regions—in patients with…
NCT07062003 First-in-human - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 3 Trial: Bleximenib Menin-MLL Inhibitor for Acute Myeloid Leukemia
This Phase 3 randomized, double-blind study evaluates whether adding investigational bleximenib (a Menin-MLL inhibitor) to venetoclax (BCL2 inhibitor) plus azacitidine (DNA methylation inhibitor) improves outcomes…
NCT06852222 Registrational
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.